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Interferon-stimulated gene 15 accelerates
replication fork progression inducing chromosomal
breakage
Maria Chiara Raso1, Nikola Djoric1, Franziska Walser1, Sandra Hess2, Fabian Marc Schmid1, Sibylle Burger1, Klaus-Peter Knobeloch2, and
Lorenza Penengo1
DNA replication is highly regulated by the ubiquitin system, which plays key roles upon stress. The ubiquitin-like modifier
ISG15 (interferon-stimulated gene 15) is induced by interferons, bacterial and viral infection, and DNA damage, but it is also
constitutively expressed in many types of cancer, although its role in tumorigenesis is still largely elusive. Here, we show that
ISG15 localizes at the replication forks, in complex with PCNA and the nascent DNA, where it regulates DNA synthesis. Indeed,
high levels of ISG15, intrinsic or induced by interferon-β, accelerate DNA replication fork progression, resulting in extensive
DNA damage and chromosomal aberrations. This effect is largely independent of ISG15 conjugation and relies on ISG15
functional interaction with the DNA helicase RECQ1, which promotes restart of stalled replication forks. Additionally, elevated
ISG15 levels sensitize cells to cancer chemotherapeutic treatments. We propose that ISG15 up-regulation exposes cells to
replication stress, impacting genome stability and response to genotoxic drugs.
Introduction
Timely and accurate DNA replication in dividing cells is crucial
to maintain the integrity of the human genome. However, due to
constitutive growth signaling and defective DNA repair, cancer
cells may exhibit replication stress, a phenomenon characterized
by perturbation of error-free DNA replication and slowing or
stalling of replication fork progression and DNA synthesis, in-
ducing genomic instability and tumorigenesis (Zeman and
Cimprich, 2014). Replication stress can arise as consequence of
normal cellular events involving DNA (i.e., replication–transcription
collisions and replication of special DNA structures, such as telo-
meres, fragile sites, and G-quadruplex), upon exposure to external
agents, including irradiation or chemotherapeutic drugs, or after
oncogene activation (Muñoz and Méndez, 2017). Although replica-
tion stress has been proven to induce genomic instability and tu-
morigenesis, recent studies have shown that enhancing replicative
stress to induce catastrophic failure of cancer cell proliferation may
provide a powerful therapeutic approach (Forment and O’Connor,
2018).
The mechanisms that underlie the cellular DNA damage re-
sponse and DNA replication stress are complex and tightly
controlled by posttranslational protein modifications, including
phosphorylation, acetylation, methylation, poly-(ADP-ribosyl)ation,
and modifications by the ubiquitin system (Wang et al., 2017).
Ubiquitin-like modifiers (UBLs) are small polypeptides whose
three-dimensional structures are strikingly similar to that of
ubiquitin, although the similarity in their amino acid sequences
to ubiquitin significantly varies (Kerscher et al., 2006). Ubiq-
uitin and UBLs have pivotal roles in the cellular response to
various forms of stress and mainly act via covalent conjugation
to target proteins. This kind of protein modification can affect
stability, subcellular localization, activity, and overall function
(Wang et al., 2017). The role of ubiquitin and the UBLs SUMO
and NEDD8 in the control of cell cycle and DNA damage re-
sponse has been extensively studied (Brown and Jackson, 2015;
Dantuma and van Attikum, 2016). However, the function of
most UBLs, including ISG15 (the first UBL identified), in ge-
nome stability is largely unknown.
As part of the innate immunity, ISG15 is robustly induced by
type I and III IFNs, in order to protect the host during pathogen
infection (Loeb and Haas, 1992; Perng and Lenschow, 2018).
ISG15 can modify many cellular proteins, in a process called
ISGylation, by conjugating its C-terminal glycine residue to ly-
sines on the targets, yet the fate of this modification is still
largely unknown. Increasing evidence suggests that ISG15 can
regulate host response also by acting as a free intracellular
molecule. An example is the stabilization of USP18 by non-
covalent binding of ISG15, which is essential to prevent aberrant
IFN signaling in humans (Zhang et al., 2015). Furthermore,
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unconjugated ISG15 can be secreted and function as a cytokine
(D’Cunha et al., 1996; Dos Santos andMansur, 2017; Swaim et al.,
2017). ISG15 expression can also be induced independently of
IFNs via the activity of p53 upon exposure to DNA-damaging
agents and irradiation or in condition of telomere shortening
(Jeon et al., 2012; Liu et al., 2004; Lou et al., 2009; Park et al.,
2016; Park et al., 2014). Interestingly, it was shown that re-
versible PCNA ISGylation relays a signaling pathway to turn off
error-prone translesion synthesis after DNA lesion bypass for
suppressing UV-induced mutagenesis as well as for resuming
normal DNA replication (Park et al., 2014).
Elevated levels of ISG15 expression occur in many types of
cancer (Andersen et al., 2006; Bektas et al., 2008; Desai et al.,
2006, 2012; Ina et al., 2010; Jinawath et al., 2004; Laljee et al.,
2013; Li et al., 2014; Padovan et al., 2002; Talvinen et al., 2006),
and in some cases, the robust expression of ISG15was reported to
support tumor growth (Burks et al., 2014; Forys et al., 2014;
Hadjivasiliou, 2012). In spite of the increasing interest on ISG15
and its clear correlation with human malignancies, its role in
tumorigenesis is still controversial and largely unexplored (Han
et al., 2018; Villarroya-Beltri et al., 2017), and its mechanism of
action is far from being clarified.
Here, we show that high levels of ISG15 expression, which
occur upon type I IFN (IFN-β) treatment and in many human
tumors, are detrimental for the cell, leading to accelerated and
deregulated DNA replication fork progression, which ultimately
results in extensive chromosomal lesions. This effect is largely
independent of ISG15 conjugation activity and relies on the
noncovalent functional interaction with RECQ1, a key helicase
involved in replication fork restart after stalling.
Results and discussion
ISG15 is localized at the DNA replication forks
To gain insight into the potential effect of ISG15 in the regulation
of genome stability, we developed different systems to modulate
ISG15 expression. To reproduce conditions of high levels of
ISG15 expression irrespective of IFN stimulation, we generated
a human osteosarcoma (U2OS) Flp-In T-REx (FIT) cell line,
which inducibly expresses FLAG-ISG15 upon doxycycline
treatment. In this cell system, ISG15 levels upon induction are
comparable to those observed upon IFN-β treatment (Fig. 1 A).
Moreover, we established ISG15 knockout (KO) in U2OS
FIT cell lines (referred as U2OS FIT ISG15/KO) via CRISPR/
Cas9-based genome editing (Fig. S1, A and B), to use as control
in different experiments.
To assess the localization of ISG15 in cells, we performed
subcellular fractionation and found that ISG15 is detectable not
only in cytosolic and nuclear soluble fractions but also in chro-
matin fractions (Fig. S1 C). To validate the presence of ISG15 in
chromatin compartments, we employed the isolation of proteins
on nascent DNA (iPOND) technique, which allows the isolation
of proteins bound, directly or indirectly, to nascent DNA at the
replication forks (Sirbu et al., 2011). Using this method, we were
able to confirm the localization of ISG15 on chromatin (Fig. 1 B;
5-ethynyl-2-deoxyuridine [EdU] +Thy chase, +click) and, most
important, at the replication forks (Fig. 1 B; EdU +click). Finally,
we adopted a cell-based method, namely the proximity ligation
assay (PLA), to visualize and measure the localization of ISG15 at
the replication forks by monitoring the close association of
ISG15 with the proliferating cell nuclear antigen (PCNA) and
newly synthesized DNA, labeled by EdU. Quantitative imaging
allowed us to evaluate the high number of PLA signals (mea-
sured as foci counts per nucleus) for ISG15/PCNA and ISG15/
EdU in cells expressing high levels of FLAG-ISG15 (Fig. 1, C–F).
Interestingly, low ISG15/PCNA PLA signal appeared also in
control cells (empty vector [EV]) likely unveiling the inter-
action of PCNA with endogenous ISG15, which is expressed at
low basal levels in U2OS cells. Accordingly, ISG15/PCNA PLA
signals are absent in the EV sample when the FLAG antibody is
used instead of ISG15 antibody (Fig. S1 D). Importantly, no
signal was detected in ISG15 KO cells or upon staining with
single antibodies (recognizing PCNA, ISG15, or EdU), con-
firming the specificity of the system (Fig. 1, D and F). These
results reveal that ISG15 localizes on chromatin at the repli-
cation forks, suggesting a possible function in modulating
DNA replication.
High levels of ISG15 accelerate DNA replication
fork progression
To determine whether ISG15 plays a role in DNA replication, we
labeled newly replicated DNA by providing cells with haloge-
nated nucleotides and performed the DNA fiber spreading assay
(Jackson and Pombo, 1998) in different experimental conditions
to evaluate replication fork progression at the single-molecule
level. Strikingly, cells expressing high levels of ISG15 exhibited
longer newly replicated tracks during the labeling period (ISG15
+ doxycycline) compared with control cells (EV, − doxycycline
and + doxycycline; Fig. 1 G). In line with this, by measuring EdU
incorporation in S phase using FACS, we observed an increased
rate of DNA synthesis in cells with high levels of ISG15, without
affecting the frequency of origin firings (Fig. S1, E and F). While
analyzing replication forks that diverge from the same replica-
tion origin, we observed no fork asymmetry, which is indicative
of frequent fork pausing usually associated with replication
stress, as observed uponmild treatment with the topoisomerase-
1 inhibitor camptothecin (CPT; 50 nM; Fig. S1, G and H). The
effect of ISG15 levels on DNA replication is dose dependent and
already detectable at early time points of doxycycline induction
(4 and 8 h; Fig. 1, H and I). Importantly, high levels of ISG15 do
not induce expression or stabilization of its deconjugating en-
zyme USP18 at the mRNA or protein level (data not shown),
thereby excluding any contribution of USP18 to the replication
phenotype observed. Taken together, these data show that ISG15
is located at DNA replication forks, where it increases the fork
progression rate in a dose-dependent manner.
IFN-β treatment increases DNA replication fork progression
through ISG15 induction
Since type I IFN is one of the main physiological inducers of
ISG15 expression, we tested the effects of IFN-β stimulation on
DNA replication in U2OS cells. To prevent the cytotoxic effects
of IFNs on cell viability, we limited the treatment to 2 h and then
chased in IFN-β–free media for different time points, tested the
Raso et al. Journal of Cell Biology 2 of 16


















































































Figure 1. ISG15 localizes at the DNA replication forks and accelerates replication fork progression. (A) ISG15 immunoblot on protein extracts of U2OS
FIT cells bearing EV or FLAG-ISG15, induced with doxycycline (dox; 1 µg/ml) for 48 h, and in parental U2OS treated with IFN-β (30 U/ml for 2 h) and chased in
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induction of ISG15 (Fig. 2 A), andmeasured the rate of replication
fork progression. Remarkably, we observed that treatment with
IFN-β recapitulates the increased DNA replication fork speed
observed in U2OS FIT cells upon doxycycline induction, which
consistently correlates with ISG15 expression levels (Fig. 2, A and
B). To assess the specific contribution of ISG15 over the many
factors regulated by IFNs, we tested the effect of IFN-β on rep-
lication fork progression in U2OS FIT ISG15/KO cells. Notably,
we found that the accelerated fork progression rate was abro-
gated in cells lacking ISG15 (Fig. 2, C and D) and restored upon
doxycycline-dependent reexpression of FLAG-ISG15 in U2OS FIT
ISG15/KO cells (Fig. 2, E and F; see Materials and methods for
details). These data clearly indicate that the increase in repli-
cation fork progression, observed upon IFN-β treatment, relies
on ISG15 expression. Additionally, to test if this is a general effect
and not restricted to U2OS cells, we generated ISG15 KO inMCF7
cells (human breast cancer; MCF7 ISG15/KO; Fig. S2 A), using the
same experimental pipeline as for U2OS FIT cells, and measured
replication fork progression upon IFN-β stimulation in parental
(WT) and MCF7 ISG15/KO cells. In line with the data obtained in
U2OS cells, we found that IFN-β accelerates fork progression in
MCF7 in a ISG15-dependent manner (Fig. 2 G). Again, accelerated
fork progression in MCF7 ISG15/KO cells was restored by stable
reexpression of ISG15 (Fig. 2 H). Our findings provide strong ev-
idence that accelerated DNA replication fork progression is pro-
moted by physiological IFN-β–mediated overexpression of ISG15.
DNA replication fork progression in ISG15-expressing cancer
cells relies on ISG15 levels
Since ISG15 expression is often up-regulated in cancer, we aimed
to investigate whether the rate of DNA replication is regulated
by ISG15 in other cancer cells in addition to U2OS and MCF7. We
analyzed the levels of ISG15 in a panel of cancer cell lines using
U2OS as reference system for ISG15 expression (Fig. S2 B). We
selected three cell lines (HeLa from cervical cancer and M059K
and T98G from glioblastoma) that exhibit relatively high levels
of ISG15 and efficient ISG15 knockdown upon transient trans-
fection of siRNAs targeting ISG15 (Figs. 2 I and S2 C). Although
HeLa, M059K, and T98G cells showed intrinsic differences in
DNA replication fork progression, depletion of ISG15 leads to a
30–40% reduction in replicated track length in all of these cell
types (Fig. 2 J). Overall, these data show that ISG15 expression
levels affect DNA replication fork progression in cancer cells of
various origin.
Accelerated replication fork progression induced by high levels
of ISG15 is largely conjugation independent
ISG15 function was mainly studied as protein modifier able to
covalently conjugate to target proteins, but it can also act as free
molecule by interacting with proteins noncovalently (Dos Santos
and Mansur, 2017; Swaim et al., 2017; Zhang et al., 2015). To
assess whether the conjugation ability of ISG15 is required for its
influence on replication, we generated U2OS FIT and U2OS FIT
ISG15/KO cell lines that express a mutant of ISG15 lacking the
C-terminal diglycine motif that is required for covalent modi-
fication of target proteins (ISG15ΔGG; Fig. 3 A). Overexpression
of ISG15ΔGG largely recapitulated the replication phenotype
observed upon overexpression ofWT ISG15 (Fig. 3 B; and Fig. S3,
A and B). Likewise, ISG15ΔGG also accelerated replication fork
progression in the context of ISG15 KO cells and localizes in close
proximity to PCNA, as revealed by PLA analysis (FLAG/PCNA),
although to a lesser extent than WT ISG15 (Fig. 3, B and C),
suggesting possible additional roles for ISG15 conjugation in
DNA synthesis. Analogous to WT ISG15, expression of ISG15ΔGG
did not induce fork asymmetry or alterations in cell cycle dis-
tribution (Fig. S3, C and D).
ISG15 consists of two tandem ubiquitin-like domains bearing
the typical β–grasp folds (Narasimhan et al., 2005), though the
sequence homology with ubiquitin is quite low (Fig. S3 E). In-
triguingly, while analyzing the crystal structure of ISG15, we
observed that the N-terminal lobe of ISG15 contains a hydro-
phobic surface, centered on L10, L72, and V74 (referred as LLV),
reminiscent of the hydrophobic patch characteristic for ubiq-
uitin (L8, I44, and V70; Fig. 3 D). This patch is strictly required
for ubiquitin functions and constitutes the recognition site of
most ubiquitin-binding domains (Hicke et al., 2005). Therefore,
we tested whether the LLV patch is required for ISG15 function.
We found that single mutations in the LLV patch significantly
reduced fork acceleration induced by high levels of ISG15, while
the triple mutant suppressed it completely (LLVAAA; Fig. 3, E
and F) without major alterations of cellular localization (Fig.
S3 F). To exclude that mutations targeting the LLV patch gen-
erally affect ISG15 protein folding, we tested the ability of L72A
and the LLVAAA mutants to conjugate to target proteins. When
mediumwithout IFN-β for 46 h before lysis. GAPDH immunoblotting is used to normalize protein loading. (B) Analysis of proteins associated with nascent DNA,
isolated by iPOND. HEK293T cells transfected with EV or myc-ISG15 for 24 h were pulse-labeled with EdU for 10 min and then chased with thymidine for 60
min. Immunoblotting with the indicated antibodies reveals the presence of ISG15 on chromatin (H3-positive fraction) and at the replication forks (H3- and
PCNA-positive fraction). (C) Representative images of ISG15 colocalization with PCNA (ISG15/PCNA), as revealed by PLA. Immunofluorescence (IF) shows
protein expression and cellular distribution of ISG15 and PCNA in U2OS FIT cells (treated with 1 µg/ml doxycycline for 48 h). Scale bars, 10 µm. (D)QIBC shows
the distribution of PLA foci counts of samples described in C. For each condition, images containing ≥1,000 cells per experiment were acquired (n = 3).
(E) Representative images of ISG15 colocalization with newly synthesized DNA (ISG15/EdU), labeled by the nucleotide analogue EdU (1 µM, 8 min), as revealed
by PLA. Immunofluorescence (IF) shows cellular distribution of ISG15 and EdU in U2OS FIT cells (treated with 1 µg/ml doxycycline for 48 h). Scale bars, 10 µm.
(F) QIBC shows the distribution of PLA foci counts of samples described in E. For each condition, images containing ≥1,000 cells per experiment were acquired
(n = 3). (G) Top: DNA fibers labeling strategy and representative image. Bottom: Analysis of IdU track length measurements in U2OS FIT cells expressing EV or
FLAG-ISG15 (treated with 1 µg/ml doxycycline for 48 h). At least 100 tracks were scored per sample (n = 5). Vertical lines represent the median value, and boxes
and whiskers show 10–90th percentiles. Statistical analysis according to Mann–Whitney test; ns, not significant; ****, P < 0.0001. (H) FLAG-ISG15 expression
in U2OS FIT cells after induction with 1 µg/ml doxycycline for the indicated time points. (I) Analysis of IdU track length measurements in U2OS FIT cells upon
ISG15 induction as in H. At least 100 tracks were scored per sample (n = 3).
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Figure 2. ISG15 expression levels impact on replication fork progression in different systems. (A) Time course of ISG15 expression in U2OS treated with
IFN-β (30 U/ml, 2 h) and chased for the indicated time points before lysis. (B) Analysis of IdU track length measurements in U2OS cells treatedwith IFN-β as in A.
At least 100 tracks were scored per sample (n = 3). (C) ISG15 protein levels in U2OS FIT cells carrying ISG15 WT or ISG15 KO treated with IFN-β (30 U/ml, 2 h)
and chased for 46 h before lysis. Phosphorylated STAT1 (pSTAT1) reveals activation of IFN-β pathway. Immunoblot with STAT1 and GAPDH are used to
Raso et al. Journal of Cell Biology 5 of 16


















































































coexpressed in HEK293T cells together with the ISG15 conju-
gation machinery (UBE1L as E1, UBCH8 as E2, and HERC5 as E3),
both ISG15 variants were as efficiently conjugated as WT ISG15
(Fig. S3 G).
Accelerated fork progression by ISG15 depends on the
functional interaction with RECQ1
To pinpoint factors potentially involved in the replication
function of ISG15, we performed mass spectrometry analysis to
search for ISG15 binding partners, rather than targets, by ana-
lyzing the chromatin factors interacting with ISG15ΔGG (Fig. 3
A; and Fig. S4, A–C). Under these conditions, we found a limited
number of potential interaction partners of ISG15 (Table S1). The
best candidates were ranked on the basis of their function and
chromatin localization. One of the most promising factors
identified was RECQ1, a key DNA helicase that binds a variety of
DNA structures, including DNA replication forks and Holliday
junctions (Popuri et al., 2008; Sharma et al., 2005), and pro-
motes the branch migration and restart of DNA replication forks
upon fork stalling (Berti et al., 2013). To validate RECQ1 inter-
action, we performed coimmunoprecipitation in HEK293T cells
overexpressing both HA-RECQ1 and myc-ISG15 and observed a
relatively modest interaction (Fig. S4 D), while no clear associ-
ation was found using recombinant proteins (data not shown),
likely suggesting that ISG15–RECQ1 interaction is difficult to
detect and study by standard biochemistry. Therefore, to better
explore the ISG15–RECQ1 interaction, we exploited the Nano-
BRET assay, based on the bioluminescence resonance energy
transfer optimized to study dynamic interactions between pro-
teins in a cellular context, due to the distance constraint of en-
ergy transfer of ∼5 nm (Machleidt et al., 2015). Importantly, this
assay revealed a clear association of RECQ1 with ISG15, both as
WT and as conjugation-defective variant, whereas no signal was
observed with p53, an unrelated protein that we used as a
control for specificity (Figs. 4 B and S4 E). To further corroborate
this result, we performed PLA on U2OS FIT cells expressing
ISG15 WT and ISG15ΔGG using antibodies against ISG15 and
endogenous RECQ1, and we obtained remarkably strong signals
in both cases, providing further evidence that RECQ1 is indeed in
a protein complex with ISG15 (Fig. 4, C and D).
Next, we addressed the functional link between ISG15 and
RECQ1 by assessing whether the expression of RECQ1 is required
for the replication phenotype observed in cells expressing high
levels of ISG15. Notably, depletion of RECQ1 completely abol-
ished the accelerated replication fork progression induced by
high levels of ISG15 and ISG15ΔGG (Fig. 4, E and F), suggesting
that ISG15may regulate RECQ1 function by unleashing its restart
activity. To test whether ISG15 promotes RECQ1-dependent fork
restart, we measured the DNA replication restart after fork
stalling using an established DNA fiber protocol that includes
a prolonged treatment with hydroxyurea (HU; 4 mM, 4 h)
between nucleotide analogue–labeling periods. In line with
previous results (Berti et al., 2013; Zellweger et al., 2015),
RECQ1-depleted cells were only partially defective in fork re-
start due to the contribution of alternative restart pathways
(Thangavel et al., 2015). Notably, cells expressing high levels of
ISG15 display accelerated restart of stalled forks, which is sup-
pressed by RECQ1 depletion, leading to a marked fork restart
defect (Fig. 4, G and H). Collectively, these data strongly suggest
that ISG15 promotes the fork restart activity of RECQ1, without
affecting RECQ1 protein levels (Fig. S4 F).
High levels of ISG15 unleash DNA replication, induce DNA
breakages, and sensitize cells to genotoxic stress
We next addressed whether high levels of ISG15 could also lead
to unrestrained replication fork progression in conditions of
mild DNA replication stress, which is typically associated with
early tumorigenesis or chemotherapeutic treatments (Berti and
Vindigni, 2016; Macheret and Halazonetis, 2015). Cells ex-
pressing high levels of ISG15 and control cells were challenged by
mild doses of genotoxic agents, which cause replication fork
slowing without detectable DNA damage (Zellweger et al., 2015),
and then subjected to DNA fiber analysis. The ratio between
5-iodo-2-deoxyuridine (IdU) and 5-chloro-2’-deoxyuridine (CldU)
was measured to assess the replication slowdown observed upon
treatment with genotoxic stress (see scheme in Fig. 5 A). As
expected, replication fork progression was significantly reduced
in control cells treated with a low dose (50 nM) of CPT (EV +
CPT). In contrast, cells expressing high levels of either WT or
ISG15ΔGG were less sensitive to CPT treatment and displayed
unrestrained fork progression (Fig. 5 A). Similar effects were
observed upon treatment with mild doses of the DNA cross-
linking agent cisplatin (cis-diamminedichloridoplatinum(II),
CDDP; 1 µM), but not with HU (0.5 mM), which, at this
normalize protein loading. (D) Top: DNA fiber–labeling strategy. Bottom: Analysis of IdU track length measurements in U2OS as in C. At least 100 tracks were
scored per sample (n = 3). Vertical lines represent the median value, and boxes and whiskers show 10–90th percentiles. Statistical analysis according to
Mann–Whitney test; ns, not significant; ****, P < 0.0001. (E) ISG15 immunoblot of parental U2OS FIT cells expressing EV or FLAG-ISG15 and U2OS FIT cells
lacking the endogenous ISG15 (U2OS ISG15/KO) and reexpressing stably integrated EV or exogenous FLAG-ISG15 after 48 h induction with 1 µg/ml doxycycline.
Western blot analysis reveals the expression of endogenous (black triangle) and exogenous (white triangle) ISG15. (F) Analysis of IdU track length meas-
urements in U2OS as in (E). At least 100 tracks were scored per sample (n = 3). Vertical lines represent the median value, and boxes andwhiskers show 10–90th
percentiles. Statistical analysis according to Mann–Whitney test; ****, P < 0.0001. (G) Top: ISG15 expression in MCF7 cells carrying ISG15 WT or ISG15 KO
treated with IFN-β (30 U/ml, 2 h) and chased for 46 h before lysis. Bottom: Analysis of IdU track length measurements. At least 100 tracks were scored per
sample (n = 3). Vertical lines represent the median value, and boxes and whiskers show 10–90th percentiles. Statistical analysis according to Mann–Whitney
test; ****, P < 0.0001; *, P < 0.05. (H) Top: ISG15 protein levels in MCF7 cells bearing the WT gene of ISG15 (MCF7) and cells lacking the endogenous ISG15
(MCF7 ISG15/KO) stably integrated with EV or FLAG-ISG15. Bottom: Analysis of IdU track lengthmeasurements. At least 100 tracks were scored per sample (n =
3). Vertical lines represent the median value, and boxes and whiskers show 10–90th percentiles. Statistical analysis according to Mann–Whitney test; ****, P <
0.0001; *, P < 0.05. (I) ISG15 knockdown (siISG15) 48 h after siRNA transfection in HeLa, T98G, and M059K cells. siLuc is used as control. (J) Analysis of IdU
track length measurements as in I. At least 100 tracks were scored per sample (n = 3). Vertical lines represent the median value, and boxes and whiskers show
10–90th percentiles. Statistical analysis according to Mann–Whitney test; ****, P < 0.0001.
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Figure 3. Accelerated replication fork progression in cells expressing high levels of ISG15 is largely conjugation independent. (A) ISG15 immunoblot of
U2OS FIT cells bearing EV, FLAG-ISG15, or FLAG-ISG15ΔGG after 48-h induction with 1 µg/ml doxycycline (dox). (B) The effect of ISG15 on DNA replication was
assessed by using DNA fiber assay in parental U2OS FIT cells (as in A) and U2OS FIT cells (ISG15 KO [U2OS ISG15/KO]; see Fig. S3 A) expressing EV, FLAG-ISG15,
or FLAG-ISG15ΔGG after doxycycline induction (1 µg/ml, 48 h). At least 100 tracks were scored per sample (n = 3). Vertical lines represent the median value,
and boxes and whiskers show 10–90th percentiles. Statistical analysis according to Mann–Whitney test; ns, not significant; ****, P < 0.0001; ***, P < 0.001.
(C) Colocalization of FLAG-ISG15 and FLAG-ISG15ΔGG with PCNA (FLAG/PCNA) in U2OS FIT cells induced for 48 h with 1 µg/ml doxycycline determined by
PLA. QIBC shows the distribution of PLA foci counts. For each condition, images containing ≥1,000 cells per experiment were acquired (n = 3). (D) Repre-
sentation of 3D structure of N-terminal ubiquitin-like domain (N-lobe) of ISG15 and ubiquitin (Protein Data Bank accession nos. 1Z2M and 1UBQ, respectively).
The residues corresponding to the hydrophobic patches are indicated. (E) U2OS FIT cells were transfected with EV, FLAG-ISG15 wild type and ISG15 mutants
carrying the indicated single amino acid substitutions (L10A, L72A, and V74A) or the combination of them (LLVAAA). (F) Analysis of IdU track length meas-
urements as in E. At least 100 tracks were scored per sample (n = 3). Vertical lines represent the median value, and boxes and whiskers show 10–90th
percentiles. Statistical analysis according to Mann–Whitney test; ns, not significant; ****, P < 0.0001.
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Figure 4. Increase of replication fork progression by ISG15 depends on the functional interaction with RECQ1. (A) Chromatin extracts were obtained
from U2OS FIT cells expressing EV or FLAG-ISG15ΔGG and processed as indicated for mass spectrometry analysis. (B) ISG15 interaction with RECQ1 was
measured as luminescence signal by NanoBRET in HEK293T cells that were cotransfected with HaloTag-Fusion constructs of ISG15 (HT-ISG15) and RECQ1
fused to NanoLuc at N-terminus (NL-RECQ1) or C-terminus (RECQ1-NL; n = 3). HT-p53 and NL-MDM2 are used as controls. (C) Representative images of
colocalization of FLAG-ISG15 and FLAG-ISG15ΔGG with endogenous RECQ1 (ISG15/RECQ1) in U2OS FIT cells after doxycycline induction (1 µg/ml, 48 h),
assessed by PLA. Scale bars, 10 µm. (D)QIBC shows the distribution of PLA foci counts of samples described in C. For each condition, images containing ≥1,000
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concentration, directly prevents fork progression by depleting
nucleotides (Fig. S4 G). Remarkably, the replication rate ob-
served in cells with high levels of ISG15 and treated with CPT
was comparable to that measured in unperturbed control cells
(Fig. 5 B), indicating that high ISG15 levels impose sustained fork
progression even in conditions of replication stress. Moreover,
the unrestrained fork progression observed in condition of high
levels of ISG15 upon CPT treatment was also abrogated by loss of
RECQ1 (Fig. 5 C), further suggesting that ISG15 unleashes RECQ1
restart activity, even in the context of replication stress.
Accelerated replication fork progression has been reported to
be detrimental for cells (Maya-Mendoza et al., 2018). Thus, we
asked whether the deregulated replication fork progression
observed in context of high levels of ISG15 results into detectable
genomic lesions. To address this point, we took advantage of the
neutral comet assay, which allows measuring the formation of
DNA double-strand breaks in different experimental conditions.
Strikingly, we found that high levels of either ISG15 or ISG15ΔGG
mutant were sufficient to induce the accumulation of DNA le-
sions in cells, and this effect was increased upon treatment with
low-dose CPT (Figs. 5 D and S4 H). This adverse effect on DNA
integrity is usually repaired in normal conditions. However, in
cells expressing high levels of ISG15, increased chromosomal
abnormalities were detected during mitosis, mostly visible as
regions of decondensed chromatin along metaphase chromatids
(Fig. 5, E and F). To examinewhether the detrimental phenotype
promoted by ISG15 impacts cell viability in response to different
drugs, we performed clonogenic survival assays. Remarkably,
the expression of high levels of ISG15 sensitized cells to low doses
of CPT and the poly (ADP-ribose) polymerase (PARP) inhibitor
(PARPi) olaparib (Fig. 5, G and H). This result supports and helps
explain previous observations, showing that high levels of ISG15
increase the sensitivity to CPT in breast cancer cells (Desai et al.,
2008) and correlate with high sensitivity to irinotecan (a clini-
cally used CPT derivative) in gastric cancer (Shen et al., 2013).
Up-regulation of ISG15 and increased ISGylation of target
proteins are well-characterized IFN-mediated responses to
pathogen infection (Perng and Lenschow, 2018) but are also
associated with pathological conditions observed in many types
of cancer. Depending on the context, either oncogenic or tumor
suppressive effects were reported (Han et al., 2018). Here, we
describe a novel unexpected function of the UBL ISG15 in the
regulation of DNA synthesis. We demonstrate that ISG15 local-
izes at DNA replication forks in close proximity to PCNA and
newly synthesized DNA. High levels of ISG15 expression, as ob-
served upon IFN induction or in our inducible cell line, dereg-
ulate replication fork progression, leading to genomic instability.
Keeping replication fork speed under tight control is essential
to preserve genome stability. While slowing down replication
fork progression is frequently observed when cells experience
replication stress (Zeman and Cimprich, 2014), an increase in
fork progression rate is far more uncommon. In the present
study, we found that expression of high levels of ISG15, as well as
its conjugation-defective form, ISG15ΔGG, causes faster and
unrestrained DNA replication fork progression. In the presence
of high levels of ISG15, the fork progression rate observed upon
mild genotoxic stress is comparable to that of untreated control
cells, strongly indicating that ISG15 dampens the active slowing
of replication fork progression in response to genotoxic agents.
As a result of this desensitization, cells accumulate chromosomal
breakage. In line with this, we found that the rate of replication
fork progression of different cancer cells constitutively ex-
pressing high levels of ISG15 is markedly reduced upon depletion
of ISG15, further supporting the role of ISG15 as a critical
modulator of replication fork progression across different cel-
lular systems.
The rate of replication fork progression may be affected by
multiple factors. Since the effect of ISG15 in replication fork
progression appears partly independent on its conjugation, we
ran a mass spectrometric analysis searching for ISG15-
interacting proteins potentially involved in the increased repli-
cation rate. Although very few chromatin-associated factors
were found, three of them (RECQ1, DEK, and SMCE1) are pro-
teins known to bind four-way junction structures, such as re-
versed replication forks that typically form in conditions of
replication stress (Quinet et al., 2017). In the present study, we
focused on the DNA helicase RECQ1, as its role in replication fork
restart upon fork stalling was already established (Berti et al.,
2013). Although a direct interaction between ISG15 and RECQ1
proved difficult to monitor and study, the two proteins were
detected in close proximity at replication forks and displayed a
clear functional interaction, as the accelerated replication fork
progression induced by high ISG15 levels is fully dependent on
RECQ1. However, as suggested by the mass spectrometry data,
ISG15 may have a more general role in regulating DNA replica-
tion at these specific replication intermediates (i.e., the four-way
junctions). Despite their close proximity, it is still unclear how
ISG15 affects RECQ1’s activity. Although other scenarios cannot
be currently excluded, we envision that ISG15 may directly
modulate the ability of RECQ1 to bind and unwind different DNA
structures at stalled forks; alternatively, by binding to stalled
forks, ISG15 may favor RECQ1-mediated fork restart. Further
studies will need to address whether and how ISG15 regulates
formation, stability, and/or restart of reversed replication forks
and whether additional factors are involved.
The detrimental effects of high ISG15 levels on DNA repli-
cation and genome stability recall recent data showing a high
speed of fork progression upon PARPi (Maya-Mendoza et al.,
cells per experiment were acquired (n = 3). (E) FLAG-ISG15 and RECQ1 protein levels in U2OS FIT cells expressing EV, FLAG-ISG15, or FLAG-ISG15ΔGG after
doxycycline induction (1 µg/ml, 48 h) and upon knockdown of RECQ1 by siRNA transfection. siLuc is used as control. (F) Analysis of IdU track length
measurements as in E. At least 100 tracks were scored per sample (n = 3). Vertical lines represent the median value, and boxes and whiskers show 10–90th
percentiles. Statistical analysis according to Mann–Whitney test; ns, not significant; ****, P < 0.0001. (G) Left: DNA fiber–labeling strategy to determine fork
restart and representative images. Right: Fork restart speed (IdU) normalized on fork speed (CldU) in U2OS FIT cells upon RECQ1 knockdown after doxycycline
induction (1 µg/ml, 48 h) as described in the scheme. At least 100 tracks were scored per sample (n = 3). Statistical analysis according to Mann–Whitney test;
ns, not significant; ****, P < 0.0001. (H) Percentage of stalled forks after HU washout in U2OS FIT cells described in G.
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Figure 5. High levels of ISG15 unleash DNA replication, induce DNA breakages and sensitize cells to genotoxic stress. (A) Top: Schematic repre-
sentation of DNA fiber assay strategy. Bottom: Effect of CPT treatment (50 nM), optionally added concomitantly with the second label (IdU), in U2OS FIT cells
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2018). Albeit not directly discussed in this report, the effect of
PARPi effect on DNA replication rate also relies on deregulation
of RECQ1, which is a key target of PARP1 negative regulation in
this context (Berti et al., 2013). In line with this, we observed
that the effect of ISG15 on replication fork progression was not
further increased by treatment with PARPi (data not shown),
suggesting that ISG15 and PARPi may affect replication fork
progression with a similar mechanism. As also supported by
recent studies using mouse models of chemoresistance (Gogola
et al., 2019), PARP1-modulated function of RECQ1 in replication
fork restart is emerging as a key regulatory process for the ef-
ficacy of anticancer treatments targeting replication. The in-
creased activity of RECQ1 by high ISG15 levels may thus
represent an important vulnerability that can be exploited for
genotoxic anticancer treatments. Furthermore, the evaluation of
ISG15 levels in tumor samples may represent a predictive pa-
rameter to stratify patients in personalized cancer therapy.
Why did cells evolve such a potentially harmful system to
counteract infection? A possible safe-lock strategy resides on the
limited availability of free intracellular ISG15. During pathogen
infection, the activation of the IFN pathway leads to the ex-
pression of several genes, including the ISG15 conjugation ma-
chinery (E1, E2, and E3) that promotes extensive ISGylation of its
target proteins and consequently reduces the free intracellular
pool of ISG15. The detrimental effects may thus arise only when
ISG15 expression and conjugation are uncoupled, resulting in
abnormally high levels of free ISG15, which promote deregulated
replication events.
Our data uncover the first physiological response (i.e., IFN-β
stimulation) directly modulating the velocity of replication fork
progression, via the induction of ISG15 expression. Recent lit-
erature demonstrates that defects in processing DNA replication
stalled forks lead to accumulation of cytosolic DNA and to acti-
vation of the cGAS–STING pathway, resulting in the activation
of the type I IFN pathway with consequent expression of ISG15
(Coquel et al., 2018). Thus, ISG15 overexpression appears as
central player in this emerging field, being at the same time a
modulator of DNA replication fork speed and a consequence of
replication stress.
Overall, ISG15 function in regulating replication fork pro-
gression and genome stability contributes to explain the com-
plex role of the IFN system, and of ISG15 itself, in tumorigenesis
and cancer therapy (Han et al., 2018). A key challenge for future
studies will be to understand if ISG15, via interaction or conju-
gation to protein partners, plays additional roles in the main-
tenance of genome integrity, impacting other fundamental
aspects of DNA replication and/or the DNA damage response
and repair, and whether its expression levels might be used to
predict sensitivity to therapeutic treatments.
Materials and methods
Chemicals and transfection reagents
Blasticidin (InvivoGen; catalog number ant-bl-1), hygromycin B
(InvivoGen; catalog number ant-hg-05), doxycycline (Sigma-
Aldrich; catalog number D9891), Geneticin (G418; Thermo
Fischer Scientific; catalog number 10131035), EdU (Sigma-
Aldrich; catalog number 900584), CldU (Sigma-Aldrich; catalog
number C6891), IdU (Sigma-Aldrich; catalog number I7125-5G),
ProLong Gold Antifade Reagent (Thermo Fisher Scientific; cat-
alog number P36930), VECTASHIELD Antifade Mounting Me-
dium (Vector Laboratories; catalog number H-1200), SYBR Gold
Nucleic Acid Gel Stain (Invitrogen; catalog number S11494), CPT
(Sigma-Aldrich; catalog number C9911), HU (Sigma-Aldrich;
catalog number H8627), cisplatin (CDDP; Sigma-Aldrich; catalog
number 232120), Nocodazole (Sigma-Aldrich; catalog number
M1404), Olaparib (Selleckchem; catalog number S1060), Sea-
Plaque GTG Agarose (Lonza; catalog number 50111), FuGENE HD
Transfection Reagent (Promega; catalog number E2311), and
JetPRIME transfection reagent (Polyplus; catalog number
114–07) were used.
Cell lines and cell culture
MCF7, HeLa, T98G, M059K, and HEK293T cells were grown in
DMEM, 10% FBS. The U2OS FIT cell line was grown in DMEM,
10% FBS tetracycline-free, complemented with blasticidin (10
µg/ml) and hygromycin B (100 µg/ml) when bearing integration.
Cellular fractionation
U2OS FIT cells were lysed in plates with hypotonic lysis buffer A
(0.01 M Hepes, pH 7.5, 0.05 M NaCl, 0.3 M sucrose, 0.5% Triton
X-100, protease inhibitor cocktail [1:100], 1 mM PMSF, 10 mM
N-Ethylmaleimide (NEM), 10 µM PJ-34, and 75 µM Tannic acid)
and incubated 15 min on ice. Cytosolic fraction was isolated after
centrifuging for 5 min at 1,500 g. Samples were incubated for
10min in nuclear lysis buffer B (0.01MHepes, pH 7, 0.2MNaCl,
expressing EV, FLAG-ISG15 or FLAG-ISG15ΔGG after doxycycline induction (1 µg/ml, 48 h). Drug effect (IdU + CPT) is normalized on CldU track length in
untreated conditions. At least 100 tracks were scored per sample (n = 3). Horizontal lines represent the median value, and boxes and whiskers show 10–90th
percentiles. Statistical analysis according to Mann–Whitney test; ns, not significant; ****, P < 0.0001. (B) Analysis of IdU track length measurements in cells
treated as in (A). At least 100 tracks were scored per sample (n = 3). Vertical lines represent the median value, and boxes and whiskers show 10–90th
percentiles. Statistical analysis according to Mann–Whitney test; ns, not significant; ****, P < 0.0001. (C) Effect of CPT treatment (50 nM) in U2OS FIT cells
expressing EV or FLAG-ISG15 after dox-induction (1 µg/ml, 48 h) and upon RECQ1 knockdown (siRECQ1). Drug effect (IdU + CPT) is normalized on CldU track
length in untreated conditions. At least 100 tracks were scored per sample (n = 3). Horizontal lines represent the median value, and boxes and whiskers show
10–90th percentiles. Statistical analysis according to Mann–Whitney test; ns, not significant; ****, P < 0.0001. (D) Neutral comet assay to measure accu-
mulation of DNA double strand breaks in U2OS FIT cells expressing EV, FLAG-ISG15 or FLAG-ISG15ΔGG induced with doxycycline (1 µg/ml) for 48 h and treated
with CPT (50 nM; n = 3). (E) Quantification of chromosomal abnormalities by analysis of metaphase spreads of U2OS FIT cells expressing EV, FLAG-ISG15, or
FLAG-ISG15ΔGG after doxycycline induction (1 µg/ml, 48 h) and treated with CPT (50 nM). At least 50 metaphases/sample were scored for every replicate.
Each spot represents average of one replicate (n = 3). (F) Representative image of chromosomal abnormalities quantified in E. Scale bar of 10 µm is indicated.
(G and H) Survival curve determined by clonogenic assay of U2OS FIT cells expressing EV or FLAG-ISG15 and treated with increasing doses of CPT (G) and the
PARP inhibitor Olaparib (H). Values are normalized on untreated and EV (n = 3).
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1 mM EDTA, 0.5% NP-40, protease inhibitor cocktail [1:100],
1 mM PMSF, 10 mMNEM, 10 µM PJ-34, and 75 µM Tannic acid).
Samples were centrifuged for 2 min at 16,000 g, and the nuclear
fractions were isolated. Pellets were resuspended in chromatin
lysis buffer C (0.01MHepes, 0.5MNaCl, 1 mMEDTA, 1%NP-40,
protease inhibitor cocktail [1:100], 1 mM PMSF, 10 mM NEM,
10 µM PJ-34, and 75 µM Tannic acid), sonicated for 15 min at low
amplitude, and centrifuged at 16,000 g, and the chromatin
fractions were isolated from the supernatant.
Co-immunoprecipitation
HEK293T cells, transfected with plasmids coding for myc-ISG15
and HA-FLAG-RECQ1 or the EV, were lysed in YY buffer (50 mM
Hepes, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100,
1 mM EDTA, and 1 mM EGTA) added with protease inhibitor
cocktail, 1 mM PMSF, 10 mM NEM, 50 mM NaF, and 10 mM
NaPyr, benzonase (100 U/ml). Cell extracts were incubated for
2 h at 4°C on a wheel with anti-HA resins (Sigma-Aldrich).
Resins were washed four times with HNTG buffer (20 mM
Hepes, pH 7.5, 150 mM NaCl, 10% glycerol, and 0.1% Triton
X-100) before elution with Laemmli buffer at 95°C.
CRISPR/Cas9 knockout of ISG15
ISG15 KO was generated in U2OS FIT (Thermo Fisher Scientific;
catalog number R78007) and MCF7 cells using a CRISPR/
Cas9D10A nickase system as described previously (Chiang et al.,
2016). Short guide RNAs (sgRNAs) were designed using UCSC
Genome Browser (GRCh38/hg38) mapping at the end of the gene
between the intron/exon region shared among all ISG15 splice
variants (chromosome 1: 1,013,559–1,013,605, 47 bp in GRCh38/
hg38) using the online tools CRISPR Design (http://www.crispr.
mit.edu) and WTSI Genome Editing (http://www.sanger.ac.uk/
htgt/wge/). sgRNA sense (59-TTACCATGGCTGTGGGCTGT-39)
and sgRNA antisense (59-CAGATGTCACAGGTGGGGGG-39; Mi-
crosynth). sgRNAs were cloned into All-in-One EGFP vector
(AIO-GFP; Addgene; Steve Jackson Lab Plasmids, #74119) that
was transfected into cells with FuGENE transfection reagent.
GFP-positive cells were sorted by FACS and single-cell plated in
96-well plates. Clones were grown and ISG15 expression was
tested by immunoblotting. 42 and 41 single clones were screened
for U2OS FIT and MCF7, respectively.
Replication fork progression by DNA fiber analysis
Asynchronous, subconfluent cells were labeled for 30 min with
30 µM of the thymidine analogue CldU and then washed with
warm PBS and labeled for 30 min with 250 µM of another
thymidine analogue, IdU, alone or in combination with geno-
toxic agents (50 nM CPT, 1 µM CDDP, or 0.5 mM HU). To
evaluate fork restart, after CldU labeling, cells were released for
4 h in fresh media containing 4 mM HU, washed with PBS, and
then labeled with IdU. Cells were collected in cold PBS, mixed 1:2
with unlabeled cells, and lysed for 8 min in 200 mM Tris-HCl,
pH 7.5, 50 mM EDTA, and 0.5% [wt/vol] SDS directly on a glass
slide. Slides were tilted at a 45°C to stretch the DNA fibers, air-
dried, and fixed in 3:1 methanol/acetic acid overnight at 4°C. The
DNA fibers were denatured for 80 min with 2.5 M HCl and
blocked for 40 min with 2% BSA/PBS-Tween. Incorporated CldU
and IdU tracks were stained for 2.5 h with anti-BrdU primary
antibodies recognizing CldU (Abcam; catalog number ab6326)
or IdU (BD Biosciences; catalog number 347580) and stained for
2 h with secondary antibody anti-mouse Alexa Fluor 488 (In-
vitrogen) and anti-rat Cy3 (Jackson ImmunoResearch; catalog
number 712–166-153). Slides were mounted with ProLong Gold
Antifade Reagent. Microscopy was done using an Olympus IX81
microscope with a charge-coupled device camera (Hamamatsu).
To assess fork progression, IdU and CldU track length of DNA
fiber molecules wasmeasured using ImageJ64 software. Value in
pixels was converted to micrometers considering the objective
lens used during acquisition (63×; conversion factor: 1 pixel =
10.54 µm). Length was converted into fork speed considering
that 1 µm DNA is composed of ∼2.59 kb (Jackson and Pombo,
1998), and nucleotide incorporation lasted for 30 min.
Generation of stable cell lines
U2OS FIT cells (and U2OS FIT ISG15/KO cells) carrying EV,
FLAG-ISG15, or FLAG-ISG15ΔGG were generated by Flp
recombinase–mediated integration (Thermo Fisher Scientific;
Flp-In T-REx Core Kit, catalog number K650001). Briefly, cells
were transfected with pcDNA5 EV, pcDNA5 FLAG-ISG15, or
pcDNA5 FLAG-ISG15ΔGG using FuGENE Transfection Reagent
together with pOG44 vector (Thermo Fisher Scientific; catalog
number V600520; 9:1 pOG44/pcDNA5) and 48 h after transfec-
tion selected for 2 wk with hygromycin B. Single clones were
isolated in plate with cloning cylinders and expanded. ISG15
expression was tested by immunofluorescence after 48 h of
doxycycline (1 µg/ml). Five clones that were comparable in
ISG15 expression were pooled together and used for experiments
wherewe referred to themas EV, ISG15, and ISG15ΔGG.MCF7 ISG15/
KO cells were transfected with pcDNA3.1 empty, pcDNA3.1 FLAG-
ISG15 using FuGENE Transfection Reagent. 24 h after transfection,
antibiotic Geneticin (800 µg/ml) was added onto the cells to select
cells that randomly integrated the vector in the genome.
Flow cytometer analysis of EdU incorporation
Cells were labeled for 30 min with 10 µM EdU, harvested, and
fixed for 10min in 4% formaldehyde/PBS. Cells were blocked for
15 min with 1% BSA/PBS, pH 7.4. Incorporated EdU was labeled
with click reaction according to the manufacturer’s instructions
(Thermo Fisher Scientific; Click-iT Plus EdU Cell Proliferation
Kit for Imaging, catalog number C10640). Total DNAwas stained
with 1 µg/ml DAPI. Samples were treated for 15 min with
100 µg/ml RNaseA and analyzed on an Attune NxT Flow Cy-
tometer (Thermo Fisher Scientific) and analyzed using FlowJo
software V.10.0.8 (FlowJo).
Immunoblotting
Whole-cell extracts were prepared in lysis in buffer 1% SDS and
50 mM Tris-HCl, pH 8.0, prewarmed at 95°C. After sonication
and clearing (15 min, 16,000 rcf), lysates were analyzed by SDS-
PAGE. 20 µg protein was solved in 8% or 12% acrylamide gel and
transferred onto a nitrocellulose membrane. The following an-
tibodies were used for immunoblotting: human-ISG15 1:1,000
(provided by K.P. Knobeloch), RECQ1 1:40,000 (Bethyl Lab-
oratories; catalog number A300-450A), FLAG M2 1:1,000
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(Sigma-Aldrich; catalog number F3166), pSTAT1 (Tyr701) 1:1,000
(Cell Signaling; catalog number 7649), STAT1 p84/p91 1:1,000
(Santa Cruz; catalog number sc-464), tubulin 1:8,000 (Sigma-
Aldrich), Lamin A 1:1,000 (Sigma-Aldrich; catalog number
L1293), GAPDH 1:50,000 (Millipore; catalog number MAB374),
H3 1:5,000 (Abcam; catalog number ab1791), PCNA 1:1,000
(Santa Cruz; catalog number sc-56), and myc (9E10) 1:1,000
(Santa Cruz; catalog number sc-40).
Immunoprecipitation and mass spectrometry analysis
Chromatin fractions, prepared as above without the sonication
step, were extracted from U2OS FIT cells expressing the EV or
FLAG-ISG15ΔGG (72 h of doxycycline induction, 1 µg/ml). 2 mg
chromatin fractions were incubated for 2 h 4°C on a wheel with
anti-FLAG resins (Sigma-Aldrich; catalog number A2220). Res-
ins were washed four times with HNTG buffer (20 mM Hepes,
pH 7.5, 150 mM NaCl, 10% glycerol, and 0.1% Triton X-100)
before elution with 0.1 M glycine (pH 2.2) for 5 min on ice.
Eluted samples were precipitated in 10% TCA and washed twice
with cold acetone. Dry pellets were dissolved in a buffer con-
taining 10 mM Tris and 2 mM CaCl2, pH 8.2, and then 0.5 µg of
trypsin was added. After digestion, samples were dried, dis-
solved in 20 µl 0.1% formic acid, and subjected to liquid chro-
matography with tandem mass spectrometry (LC/MS/MS) at
the Functional Genomic Center Zurich. All MS/MS samples
were analyzed using Mascot (Matrix Science, London, UK;
version 2.5.1.3). Mascot was set up to search the SwissProt_
autoup_20180912 database (selected for Homo sapiens, un-
known version, 20,395 entries). Mascot was searched with a
fragment ion mass tolerance of 0.030 D and a parent ion toler-
ance of 10.0 PPM. Oxidation of methionine was specified in
Mascot as a variable modification. Scaffold (Proteome Software;
version Scaffold_4.8.9) was used to validate MS/MS based
peptide and protein identifications. Peptide identifications were
accepted if they could be established at greater than 21.0%
probability to achieve a false discovery rate (FDR) less than 0.1%
by the Scaffold Local FDR algorithm. Protein identifications were
accepted if they could be established at greater than 94.0%
probability to achieve an FDR <1.0% and contained at least two
identified peptides. Protein probabilities were assigned by the
Protein Prophet algorithm (Nesvizhskii et al., 2003). Proteins
that contained similar peptides and could not be differentiated
based on MS/MS analysis alone were grouped to satisfy the
principles of parsimony. Proteins sharing significant peptide
evidence were grouped into clusters.
IFN-β stimulation
U2OS FIT andMCF7 cells were treated for 2 h in complete media
complemented with 30 U/ml IFN-β (PeproTech; catalog number
300-02BC), washed with warm PBS, and released in fresh media
for 46 h unless otherwise explained; ISG15 induction and IFN-β
activity (phosphorylation of Tyr 701 of STAT1, pSTAT1; Cell
Signaling; catalog number 7649) were tested by immunoblotting.
ISGylation machinery transfection
HEK293T cells were transfected with calcium phosphate using
2 µg pcDNA3 carrying EV, FLAG-ISG15 WT, or FLAG-ISG15
mutants (ΔGG, L72A, LLVAAA) with or without ISGylation ma-
chinery components: 4 µg UBE1L (E1), 2 µg of UBCH8 (E2), and
4 µg HERC5 (E3) and then collected for Western blot analysis
after 48 h.
iPOND
iPOND was performed as previously described (Sirbu et al.,
2011). Briefly, exponentially growing cells HEK293T cells were
transfected with EV or myc-ISG15 with calcium phosphate. After
48 h, cells were incubated for 10 min with 10 µM EdU, cross-
linked with 1% formaldehyde, harvested, and permeabilized. For
thymidine-chase controls (Thy-chase), cells were incubated for
10 min in 10 µM EdU, washed and incubated for 1 h with me-
dium containing 10 µM thymidine, and then cross-linked for
5 min with 1% formaldehyde in PBS. Biotin azide was covalently
attached to EdU within newly replicated DNA using Click
reaction, and EdU-containing DNA was precipitated using
streptavidin–agarose beads (Millipore; catalog number 69203).
EdU coprecipitates were boiled in Laemmli buffer and then
analyzed by immunoblotting.
Metaphase spreading
Asynchronously and subconfluent cells were incubated for 16 h
in fresh medium containing 200 ng/ml nocodazole. Cells were
collected by trypsinization and swollen for 20 min at 37°C with
75mMKCl. The swollen mitotic cells were fixed in 3:1 methanol/
acetic acid solution and subsequently spread dropwise onto
prehydrated glass microscopy slides and air-dried overnight.
The slides weremounted the following day using VECTASHIELD
Antifade Mounting Medium with DAPI. Images of randomly
selected metaphases were acquired by Leica DM6 B upright
digital microscope equipped with a DFC360 FX Leica camera.
Images were analyzed using ImageJ64, and chromatid breaks/
gaps were counted.
NanoBRET
HEK293T cells were cotransfected with HaloTag-Fusion con-
struct (2 µg; Promega) and varying concentrations of Nluc-
fusion vector (MDM2, 200 ng; RECQ1, 20 ng; Promega). After
20 h, cells were mixed with the HaloTag binding ligand 618 and
replated 2 × 104 cells per well on a white flat-bottom 96-well
plate and incubated for 18–24 h. Luciferase substrate was added
(Furimazine) to each well, and then Luminescence signal
(counts/second) was measured using the Tecan Spark Machine.
NanoBRET ratio was calculated by dividing the acceptor signal
by the donor signal. Subsequently, the no-ligand control was
subtracted from the ligand sample.
Neutral comet assay
U2OS FIT were induced for 7 d with doxycycline 1 µg/ml and
treated for 1 h with 50 nM CPT and washout (3 h). Cells were
collected and resuspended in cold PBS. 2 × 104 cells were mixed
with 0.8% wt/vol low melting point, previously equilibrated to
37°C, and then spread onto a comet slide (Trevigen; CometAssay
Kit, catalog number 4250–050-ESK). Slides were incubated for
20 min at 4°C to allow solidification of the low melting point.
Cells were lysed overnight in lysis buffer (Trevigen). Slides were
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incubated in cold electrophoresis buffer (300 mM sodium ace-
tate and 100mMTris, pH 8.3) for 1 h at 4°C and then subjected to
electrophoresis for 30min at 21 V/300mA. Samples were rinsed
twice in water, fixed in 70% ethanol for 20 min at 4°C, and then
dried at 37°C. DNA was stained with SYBR Gold (Thermo Fisher
Scientific). Microscopy was performed on a Leica DM6 B upright
digital research microscope equipped with a DFC360 FX Leica
camera at 10× magnification. The images were analyzed using
the Open Comet plugin (http://www.cometbio.org) for Fiji.
PLA
FIT cells were induced 48 h with doxycycline (1 µg/ml) and
grown on sterile 12-mm diameter glass coverslip, washed with
cold PBS, and preextracted and fixed in 100% cold MeOH for
10 min. After washing three times with PBS, cells were per-
meabilized for 10min at room temperature in 0.3% Triton X-100
in PBS andwashed twice in PBS. Coverslips were then incubated
with primary antibodies overnight: FLAG 1:1,000 (Sigma-
Aldrich; catalog number F7425), PCNA 1:100 (Santa Cruz; catalog
number sc-56), ISG15 1:1,000 (kindly provided by K.P. Knobe-
loch, Freiburg, Germany), and RECQ1 (A-9) 1:500 (Santa Cruz;
catalog number sc-166388). 25 µM EdU was added to media for
10 min before fixing (10 min) MeOH and permeabilizing (10
min) with 0.3% Triton X-100; EdU was linked to biotin-NaN3
with click chemistry and then immunolabeled with anti-BIOTIN
antibody Mo 1:500 (Jackson ImmunoResearch, Catalog number
200–002-211). After PBS washes, cells were incubated with
mouse PLUS probe (Sigma-Aldrich, Catalog number DUO82001)
and rabbit MINUS probe (Sigma-Aldrich; catalog number
DUO82005) for 1 h at 37°C. Ligation was performed in ligation
buffer (Sigma-Aldrich; catalog number DUO82009-1000Rxn)
with Ligase (Sigma-Aldrich; catalog number DUO82027-1EA)
for 30 min at 37°C and followed by amplification using Am-
plification Buffer Far Red (Sigma-Aldrich; catalog number
DUO82028Rxn) and Polymerase (Sigma-Aldrich; catalog number
DUO82028-1EA) for 100min at 37°C. Cells were thenwashedwith
0.2 M Tris, 0.1 M NaCl buffer and incubate for 15 min at RT with
DAPI (0.5 µg/ml). Coverslips were mounted using ProLong Gold
Antifade Reagent.
QIBC
Automated multichannel wide-field microscopy for quantitative
image-based cytometry (QIBC) was performed on an Olympus
ScanR Screening System equipped with wide-field optics, a
UPLSAPO 20× (0.75 NA), an inverted motorized Olympus IX83
microscope, a motorized stage, infrared (IR)-laser hardware
autofocus, a fast emission filter wheel with single-band emission
filters, and a 12-bit digital monochrome Hamamatsu ORCA-
FLASH 4.0 V2 sCMOS (scientific complementary metal–oxide–
semiconductor) camera (2,048 × 2,048 pixels). Images containing
≥1,000 cells per condition were acquired under nonsaturating
conditions, and identical settings were applied to all samples
within one experiment. Images were processed and analyzed with
the inbuilt Olympus ScanR Image Analysis Software (version
3.0.0), a dynamic background correction was applied, nuclei
segmentation was performed using an integrated intensity-based
object detection module using the DAPI signal, and foci
segmentation was performed using an integrated spot-detection
module. Fluorescence intensities were quantified and are depicted
as arbitrary units. These values were exported and analyzed with
Spotfire data visualization software (TIBCO software version 7.0.1;
https://www.tibco.com/products/tibco-spotfire). Within one ex-
periment, similar cell numbers were compared for the different
conditions. To visualize discrete data in scatterplots, mild jitteringwas
applied to demerge overlapping data points. Representative scatter-
plots and quantifications of independent experiments are shown.
siRNA knockdown
Cells were plated and transfected the following day with siRNA
oligonucleotides targeting ISG15 (59-GCAACGAAUUCCAGGUGU
C-39), RECQ1 (59-UUACCAGUUACCAGCAUUAUUdTdT-39), or
luciferase (59-CUUACGCUGAGUACUUCGAdTdT-39) at a final
concentration of 40 nM. Transfections were performed using
JetPRIME according to the manufacturer’s instruction 48 h after
transfection for ISG15 knockdown. For RECQ1 knockdown,
transfection was repeated after 24 h. Transfection medium was
replaced with complete medium after 24 h and protein depletion
confirmed 48 h after the second transfection by immunoblotting.
Site-specific mutagenesis
pcDNA3.1 FLAG-ISG15 was mutagenized using the following
primers: L10A forward, 59-GACCTGACGGTGAAGATGGCGGCG
GGCAACGAATTCC-39; L10A reverse, 59-GGAATTCGTTGCCCG




TGCGACG-39; and V74A reverse, 59-CGTCGCATTTGTCCACCG
CCAGCAGGACCGTGCTGCC-39; pcDNA3.1 FLAG-ISG15L10A was
mutagenized using the following primers: 3X forward, 59-GGC
AGCACGGTCGCGCTGGCGGTGGACAAATGCGACG-39; 3X re-
verse, 59-CGTCGCATTTGTCCACCGCCAGCGCGACCGTGCTGC
C-39. PfuTurbo DNA polymerase (Agilent Technologies; Pfu,
catalog number 600250) was used for the reaction and checked
on a 0.8% agarose gel. Template was digested with 1 µl DpnI
(New England Biolabs; catalog number R0176S) and TOP10
(bacteria; Thermo Fisher Scientific; catalog number C4040-03)
were transformed with mutagenized vector overnight at 37°C.
Mutated vectors were sequenced using cytomegalovirus (CMV)
primer (59-CGCAAATGGGCGGTAGGCGTG-39).
Survival assay
Cells were seeded in 96-well plate and treated the day after with
the genotoxic agents CPT (1, 5, 25, 50, and 150 nM) and Olaparib
(0.5, 1, 5, and 10 µM) for 7 to 10 d. Resulting colonies were fixed
with 100% cold MeOH and stained with 0.05% crystal violet in
100%MeOH for up to 2 h. Excess was washed out and cells were
destained for 30 min with MeOH. Crystal violet in suspension
was analyzed by measuring the absorbance at 600 nm using
SpectraMaxi3.
Statistics
The number of forks (fiber assay), nuclei (comet assay) or
metaphase scored in the shown replicate and number of
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biological replicates is defined in the figure legends. Results
were analyzed in GraphPad using a Mann–Whitney U test (two-
tailed P value; P value > 0.05 was considered not significant).
Flow cytometry data were analyzed using FlowJo software
V.10.0.8 (https://www.flowjo.com/). The intensity values of
EdU-positive cells per sample were extracted from the raw data
and subjected to statistical analysis using GraphPad Prism 7
(two-tailed P value). In the neutral comet assay, double strands
were evaluated measuring Olive tail moment (Olive moment),
a parameter that includes the tail length and the fraction of
total DNA in the tail, using the Open Comet plugin (http://
www.cometbio.org/) for Fiji. The results were analyzed using
GraphPad Prism7 using a Mann–Whitney test. Results were
displayed as scatterplots with mean and SD. In the clonogenic
assay, absorbance of each sample (technical triplicate) was
normalized on untreated samples and on the corresponding
treated EV sample.
Online supplemental material
Fig. S1 shows the pipeline for the generation of the ISG15 KO,
analysis of representative clones in U2OS, and additional ex-
periments on the ISG15 localization at the replication forks and
the effect of its deregulated expression on DNA synthesis. Fig. S2
shows analysis of representative ISG15 KO clones in MCF7 and
expression of ISG15 in different cancer cell lines. Fig. S3 reports
additional experiments on the effect of the expression of the
conjugation-defective form of ISG15 (ISG15ΔGG) in DNA syn-
thesis and cell cycle profile, as well as a sequence alignment of
human ISG15 and ubiquitin and further characterization of the
ISG15 mutants tested in the replication phenotype. Fig. S4 shows
the immunoprecipitation experiment performed for mass
spectrometry studies, additional details of the ISG15–RECQ1 in-
teraction, and the detrimental effects of expression of ISG15 and
ISG15ΔGG in DNA replication fork progression and DNA damage
upon a mild dose of replication stress. Table S1 reports the in-
teracting factors identified by mass spectrometry.
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Figure S1. ISG15 localizes at the DNA replication forks and accelerates replication fork progression. (A) Schematic representation of the pipeline
followed for the generation of CRISPR/Cas9-mediated ISG15 KO cell lines. (B) Analysis of ISG15 protein levels in 7 of the 42 single clones tested, obtained from
the CRISPR/Cas9 KO in U2OS FIT cells. Clone D3 was selected and used for the following experiments (in the main text referred to as U2OS ISG15/KO). 50 µg
cell extracts was analyzed by Western blotting as indicated. (C) Subcellular localization of ISG15 in U2OS FIT cells expressing EV or FLAG-ISG15 after 48 h
induction with 1 µg/ml doxycycline. Indicated are the different fractions analyzed. (D) Quantification of PLA foci counts by automated microscopy (QIBC) of
FLAG-ISG15 colocalization with PCNA (FLAG/PCNA) determined by PLA in U2OS FIT cells after induction with 1 µg/ml doxycycline for 48 h. For each condition,
images containing ≥1,000 cells per experiment were acquired (n = 3). (E) U2OS FIT cells after doxycycline induction (1 µg/ml, 48 h) and grown in media
supplemented with 10 µM EdU for 30 min before collecting and processing for FACS analysis. Left: DNA content (DAPI) and DNA synthesis, indicated by EdU
incorporation (FITC) measured by FACS. Right: Quantification of EdU incorporation of cells in S phase. Similar results were obtained in at least one independent
experiment. (F) Percentage of origin firing events in U2OS FIT expressing either the EV or FLAG-ISG15 after doxycycline induction (1 µg/ml, 48 h). Origin firing
events were evaluated by fibers assay (IdU-CldU-IdU) scoring ≥200 DNA fibers per experiment; each point indicates a single experiment. The line connects
values for EV and FLAG-ISG15 of the same experiment. (G) Graphical scheme of sister forks imaging by DNA fiber assay with representative image. (H) Sister
forks symmetry plot in U2OS FIT cells after doxycycline induction (1 µg/ml, 48 h). U2OS FIT cells expressing EVwere treated with CPT (50 nM, 1 h; EV + CPT) as
a positive control for asymmetry. Each fork is described by the length of left and right IdU tracks. Red lines define a range of 30% difference between left and
right tracks; left > right + 30% and right > left + 30% are considered asymmetric. Similar results were obtained in at least one independent experiment.
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Figure S2. ISG15 expression levels impact replication fork progression in different systems. (A) Analysis of ISG15 protein levels in 12 of the 41 single
clones tested, obtained from the CRISPR/Cas9 KO in MCF7 cells. Clone 1E was selected and used for the following experiments (in the main text referred to as
MCF7 ISG15/KO). (B) ISG15 immunoblot on different cellular system/conditions used in our experiments and several cancer cell lines. HeLa were derived from
cervical carcinoma; LS174T, SW620, and HT-29 were derived from colon cancer; M059K and T98G were derived from glioblastoma; DU145 and LNCaP were
derived from prostate cancer. (C) Test of ISG15 knockdown efficiency in different cancer cell lines. Cells were transfected with siISG15 or siLuc as a control and
collected after 24 h, and ISG15 levels were evaluated by Western blot analysis.
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Figure S3. Accelerated replication fork progression in cells expressing high levels of ISG15 is largely conjugation independent. (A) ISG15 immunoblot
on U2OS FIT cells expressing EV or FLAG-ISG15 and in U2OS FIT cells lacking the endogenous ISG15 (U2OS ISG15/KO) and reexpressing EV, FLAG-ISG15, or
FLAG-ISG15ΔGG after doxycycline induction (1 µg/ml, 48 h). (B) Quantification of EdU incorporation in S phase of U2OS FIT cells expressing EV or FLAG-
ISG15ΔGG after doxycycline induction (1 µg/ml, 48 h) and grown in the presence of EdU (10 µM for 30 min) before collecting and processing for FACS analysis.
Similar results were obtained in at least one independent experiment. (C) Fork asymmetry analysis in U2OS FIT expressing EV or FLAG-ISG15ΔGG after
doxycycline induction (1 µg/ml, 48 h). Each fork is described by the length of left and right IdU tracks. Red lines define a range of 30% difference between left
and right tracks; left > right + 30% and right > left + 30% are considered asymmetric. Similar results were obtained in at least one independent experiment.
(D) Left: Cell cycle profile of U2OS FIT cells expressing EV, FLAG-ISG15, or FLAG-ISG15ΔGG after 48-h induction with doxycycline. Right: Percentage of cell
distribution in different cell cycle phases. (E) Sequence alignment of human ISG15 and ubiquitin (UB). The N- and C-lobes are indicated by bars. The conserved
residues are in red. The residues that are part of the hydrophobic patch are indicated by asterisks (*). (F) Localization of ISG15 in U2OS FIT cells after
doxycycline induction (1 µg/ml, 48 h). ISG15 immunostaining was performed after preextraction and MeOH fixation. Scale bars, 10 µm. (G) The indicated forms
of ISG15 were expressed in HEK293T cells with or without the ISGylation machinery components UBE1L (E1), UBCH8 (E2), and HERC5 (E3). After 48 h, cell
extracts were collected for Western blot analysis with the indicated antibodies.
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Table S1 is provided online and shows the identification proteins interacting with ISG15; Y (green) indicates factors associated with
chromatin structures, and N (red) indicates factors that are not chromatin associated.
Figure S4. Increased replication fork progression by ISG15 depends on RECQ1 and leads to unrestrained DNA replication and DNA breakages.
(A) FLAG-immunoblot on protein extracts derived from cytosolic or nuclear fractions of U2OS FIT cells expressing EV or FLAG-ISG15ΔGG. Lamin A and GAPDH
are used as controls of fractionation and loading. (B) FLAG-ISG15 was immunoprecipitated (IP FLAG) from nuclear extracts as in A and analyzed by FLAG
immunoblot. Sn, supernatant after immunoprecipitation. (C) FLAG immunoprecipitation as in B, detected by Coomassie blue staining. The band corresponding
to FLAG-ISG15ΔGG is indicated. HL and LC represent heavy and light chain of the FLAG antibody, respectively. (D) Anti-HA immunoprecipitation from
HEK293T cells expressing HA-RecQ1 and myc-ISG15 followed by immunoblot with the indicated antibodies. TCL, total cell extracts. (E) HEK293T cells were
transfected with 2 µg expression constructs of indicated proteins. Immunoblot was used to detect HaloTag, NanoLuc, and GAPDH. (F) RECQ1 protein levels in
U2OS FIT expressing FLAG-ISG15 after induction with 1 µg/ml doxycycline (dox) for different time points indicated. Vinculin immunoblot is used as loading
control. (G) Effect of 1 µM cisplatin (CDDP) or 0.5 mM HU treatment on U2OS FIT cells expressing EV, FLAG-ISG15, or FLAG-ISG15ΔGG after induction with
1 µg/ml doxycycline for 48 h. UN, untreated. Drug effect (IdU + drug) is normalized on CldU track length in untreated conditions. At least 100 tracks were
scored per sample (n = 3). (H)Neutral comet assay to measure DNA double-strand breaks in U2OS FIT cells expressing EV, FLAG-ISG15, or FLAG-ISG15ΔGG after
induction with 1 µg/ml doxycycline for 7 d and treated with 50 nM CPT (n = 3). Statistical analysis according to Mann–Whitney test; ****, P < 0.0001.
Raso et al. Journal of Cell Biology S5
Interferon accelerates replication fork rate https://doi.org/10.1083/jcb.202002175
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
://ru
p
re
s
s
.o
rg
/jc
b
/a
rtic
le
-p
d
f/2
1
9
/8
/e
2
0
2
0
0
2
1
7
5
/1
0
4
7
3
4
7
/jc
b
_
2
0
2
0
0
2
1
7
5
.p
d
f b
y
 g
u
e
s
t o
n
 0
1
 O
c
to
b
e
r 2
0
2
0
